| 2.28 -0.04 (-1.72%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.97  |
1-year : | 3.18 |
| Resists | First : | 2.55 |
Second : | 2.73 |
| Pivot price | 2.52 |
|||
| Supports | First : | 2.25 |
Second : | 1.88 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 2.52 |
| MA(100) : | 2.71 |
MA(250) : | 2.27  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6 |
D(3) : | 9 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 3.47 | Low : | 1.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CERS ] has closed below the lower bollinger band by 1.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CERS ] is to continue within current trading range. Bollinger Bands are 30.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.37 - 2.39 | 2.39 - 2.4 |
| Low: | 2.22 - 2.24 | 2.24 - 2.26 |
| Close: | 2.25 - 2.28 | 2.28 - 2.31 |
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Thu, 01 Oct 2026
Bank of America Corp DE Acquires 868,457 Shares of Cerus Corporation $CERS - MarketBeat
Tue, 25 Aug 2026
Cerus Corporation (NASDAQ:CERS): When Will It Breakeven? - Moomoo
Tue, 18 Aug 2026
Cerus: This Blood-Safety Underdog Should Be Earning More Respect (NASDAQ:CERS) - Seeking Alpha
Thu, 30 Jul 2026
Earnings call transcript: Cerus beats Q2 2026 estimates but shares fall after hours - Investing.com
Thu, 30 Jul 2026
Cerus Corp (NASDAQ:CERS) Drops 10% After Q2 Revenue Beat Overshadowed by Lowered Full-Year Guidance - ChartMill
Mon, 08 Jun 2026
Cerus Corporation Closes New Debt Facility of Up to $110 Million - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 202 (M) |
| Shares Float | 195 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 73.3 (%) |
| Shares Short | 17,330 (K) |
| Shares Short P.Month | 13,690 (K) |
| EPS | -0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -3.1 % |
| Operating Margin | -3.3 % |
| Return on Assets (ttm) | -0.5 % |
| Return on Equity (ttm) | -10.8 % |
| Qtrly Rev. Growth | 9.5 % |
| Gross Profit (p.s.) | 0.57 |
| Sales Per Share | 1.09 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -76 |
| PEG Ratio | 0 |
| Price to Book value | 6.51 |
| Price to Sales | 2.07 |
| Price to Cash Flow | 189.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|